ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,927Medicare Part D Prescriptions Filled, Including Refills

Rank: 59 out of 1269

$580K Total Retail Price of All Prescriptions

Rank: 103 out of 1269

364 Patients Receiving at Least One Drug in Part D
72%Patients 65 Years and Older
76% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

16% of this provider’s 364 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

7% of this provider’s 364 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

2% of this provider’s 8,337 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$53 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

30 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
LISINOPRIL 431 321 1 1
AMLODIPINE BESYLATE 395 307 2 2
SIMVASTATIN 392 334 3 3
LEVOTHYROXINE SODIUM 374 319 4 4
FUROSEMIDE 357 295 5 5
METOPROLOL TARTRATE 334 236 6 6
WARFARIN SODIUM 270 184 7 12
OMEPRAZOLE 247 180 8 8
ATENOLOL 186 111 9 14
MIRTAZAPINE 183 163 10 24
POTASSIUM CHLORIDE 145 115 11 26
GABAPENTIN 145 84 11 17
HYDROCHLOROTHIAZIDE 143 87 13 10
CITALOPRAM HBR 137 106 14 21
TRAMADOL HCL 126 90 15 16
RISPERIDONE 122 93 16 43
CLOPIDOGREL 114 94 17 32
DIVALPROEX SODIUM 112 84 18 54
ATORVASTATIN CALCIUM 111 85 19 7
TRAZODONE HCL 108 76 20 36
DONEPEZIL HCL 108 107 20 22
METFORMIN HCL 106 61 22 9
PLAVIX 105 87 23 47
LEVETIRACETAM 103 72 24 55
NAMENDA 102 102 25 38
SERTRALINE HCL 95 82 26 23
GLIPIZIDE 92 72 27 37
LOVASTATIN 92 57 27 30
OXYBUTYNIN CHLORIDE ER 92 71 27 130
CARVEDILOL 90 88 30 29
QUETIAPINE FUMARATE 84 70 31 53
PRAVASTATIN SODIUM 83 51 32 11
PREDNISONE 82 79 33 45
TAMSULOSIN HCL 77 74 34 31
PANTOPRAZOLE SODIUM 76 68 35 18
CYMBALTA 72 64 36 70
ESCITALOPRAM OXALATE 72 64 36 58
RANITIDINE HCL 70 48 38 27
KLOR-CON M20 65 58 39 60
ZOLPIDEM TARTRATE 63 44 40 19
LACTULOSE 62 29 41 67
GLYBURIDE 61 57 R 42 94
HYDRALAZINE HCL 56 37 43 48
TERAZOSIN HCL 55 55 44 111
OXYCODONE HCL 55 20 S2 44 34
OXYBUTYNIN CHLORIDE 54 44 46 128
HYDROCODONE-ACETAMINOPHEN 53 46 S3 47 20
BENZTROPINE MESYLATE 53 53 R 47 108
CLONIDINE HCL 51 42 49 51
SPIRIVA 51 36 49 64
LANTUS 51 33 49 39
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.